RxDoctor Payments Data

Terry Ham, MD

Internal Medicine · Perry, GANPI 1306891650

Payments from drug & device makers

$7,222in general payments, 2019–2025

Across 420 payments — averaging $17.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$849
  • Lilly USA, LLC$797
  • Astellas Pharma US Inc$675
  • Amgen$608
  • Pfizer$602
  • AbbVie$519
  • plus $3K from 41 others

What the payments were for

  • Food & beverage$7,04798%
  • Education$1752%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,222 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$345,168
Medicare patients
1,217
Services billed
4,893

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide142$199,227
EliquisApixaban199$179,043
FarxigaDapagliflozin Propanediol174$156,374
JardianceEmpagliflozin112$116,895
MounjaroTirzepatide104$111,117
JanuviaSitagliptin Phosphate81$68,045
TrulicityDulaglutide67$64,030
MyrbetriqMirabegron89$60,637
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$37,402
GlatopaGlatiramer Acetate13$34,948
JanumetSitagliptin Phos/Metformin Hcl42$33,970
Repatha SureclickEvolocumab39$31,982
XareltoRivaroxaban34$31,726
LinzessLinaclotide23$27,441
Janumet XrSitagliptin Phos/Metformin Hcl32$25,107

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$849$199,227142 claims
PfizerEliquis$602$179,043199 claims
Lilly USA, LLCMounjaro, Trulicity$797$175,147171 claims
AstraZenecaFarxiga, Symbicort$472$161,930196 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$279$135,433146 claims
MerckJanuvia, Janumet, Janumet Xr, Belsomra$151$132,490167 claims
Astellas Pharma US IncMyrbetriq$675$60,63789 claims
GSKTrelegy Ellipta, Breo Ellipta$379$46,58948 claims
AbbVieLinzess, Synthroid$519$37,053130 claims
Johnson & JohnsonXarelto$12$31,72634 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$37$7,974671 claims
Esperion Therapeutics, Inc.Nexlizet$12$7,83714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Perry

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →